Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia/Lymphoma

Cytometry B Clin Cytom. 2019 Jul;96(4):256-265. doi: 10.1002/cyto.b.21833. Epub 2019 Jun 24.

Abstract

In this review, we discuss applications of flow cytometric immunophenotyping (FCI) in the diagnostic evaluation and posttreatment monitoring of B and T lymphoblastic leukemia/lymphoma. We describe practical approaches to FCI at the time of diagnosis, with an emphasis on blast identification, lineage assignment, and distinction of B and T lymphoblastic leukemia/lymphoma from their morphologic and immunophenotypic mimics. We further review flow cytometric assays for the detection of minimal or measurable residual disease (MRD) after treatment, and illustrate both standard approaches, and newer strategies for improving sensitivity and circumventing the loss of immunophenotypic targets after immunotherapy. © 2019 International Clinical Cytometry Society.

Keywords: acute lymphoblastic; flow cytometry; immunophenotyping; rare event detection.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Flow Cytometry*
  • Humans
  • Immunophenotyping*
  • Lymphoma / diagnosis*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis*
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis*